Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity (opens in new tab)
Ultragenyx (RARE) outlook: 2026 revenue guidance, cost controls, and key FDA/PDUFA catalysts (DTX401, UX111, GTX-102).
Read the original articleUltragenyx (RARE) outlook: 2026 revenue guidance, cost controls, and key FDA/PDUFA catalysts (DTX401, UX111, GTX-102).
Read the original article